Kratom; authorize regulation of and prohibit certain products.
SB 2736 creates the Mississippi Kratom Consumer Protection Act, a new regulatory framework for kratom products sold in the state. The bill defines kratom products and the businesses that handle them, then prohibits processors and retailers from preparing, distributing, or selling kratom products that are adulterated, contaminated, contain synthetic alkaloids, exceed a specified 7-hydroxymitragynine threshold, or lack adequate consumer labeling, including a recommended serving size.
The bill also sets a minimum age of 21 for kratom sales and authorizes the Department of Revenue to administer the act and adopt enforcement rules. Violations of the product-safety provisions can result in administrative fines of up to $1,000 for a first offense and up to $5,000 for repeat offenses, while retailers may avoid liability in some cases by showing good-faith reliance on a manufacturer or distributor's representations. The act would take effect July 1, 2025.
This bill would add a new chapter of state-level consumer protection and product-safety rules specific to kratom, affecting manufacturers, processors, distributors, retailers, and consumers in Mississippi. It would not ban kratom outright, but it would impose labeling, purity, composition, and age-restriction requirements, and it would give the Department of Revenue rulemaking and enforcement authority over compliance. The bill also references existing controlled-substance-related statutory lists to define prohibited contaminants, tying kratom enforcement to broader state drug and food-safety law.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the measure appears to be framed as a consumer-protection and public-health bill rather than a prohibition bill. The overall tone is regulatory and precautionary, focusing on product safety, transparency, and youth access restrictions. No formal vote record or transcript is available here to show organized support or opposition.
The main points of potential contention are the bill’s treatment of kratom as a regulated consumer product versus a substance that some stakeholders may want more tightly restricted or banned. Retailers and processors may be concerned about compliance costs, testing, labeling, and liability for product representations, while public-health advocates may focus on the risks posed by adulterated products, synthetic alkaloids, and youth access. The 21-and-over sales restriction and the 2% cap on 7-hydroxymitragynine are likely to be the most debated substantive limits, along with the Department of Revenue’s enforcement role.